We are grateful to this group to have confirmed our earlier results published in 2012 and 2017 using exactly similar protocol and evaluation. This is the 3rd paper validating our approach that is now the basis for an FDA/EMA approved large worldwide phase 3 trials conducted with Servier. The current publication also provides some support to our current suggested MoA.
It is important to also stress that brain imaging and eye tracking experiments conducted by Hadjikhani have also confirmed the ameliorations observed with this treatment (Hadjikani et al. 2012, 2015, 2018). The convergence of these observations is promising raising the possibility, that still needs to be confirmed in a large clinical trial, that we might have the first treatment of ASD of Autism core symptoms.